Anizatrectinib

Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM, compound 2 extracted from patent WO2015175788. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al[1].

Product Specifications

CAS Number

[1824664-89-2]

Product Name Alternative

HTrkA-IN-1

UNSPSC

12352005

Target

Trk Receptor

Type

Reference compound

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/anizatrectinib.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=C(C)C(C2=CN=C(C)N=C2)=NN1C3=CC=CC=C3)N[C@@H]4CN(CCOC)C[C@H]4C5=CC=CC(F)=C5

Molecular Formula

C29H32FN7O2

Molecular Weight

529.61

References & Citations

[1]Shelley Allen, et al. 1- ((3s,4r) -4- (3-fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-yl) -3- (4-methyl-3- (2-methylpyrimidin-5-yl) -1-phenyl-1h-pyrazol-5-yl) urea as a trka kinase inhibitor. Patent WO2015175788A1.